ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	7/13/1970
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Borrelia burgdorferi Antibodies, IgG and IgM by Immunoblot (CSF) Reflex

ARUP test code 3016761

Borrelia burgdorferi Ab, IgG, IB (CSF)	Negative	(Ref Interval: Negative)

Band(s) present: 41, 18 kDa
(Insufficient number of bands for positive result)

INTERPRETIVE INFORMATION: Borrelia burgdorferi Ab, IgG, IB (CSF)

For this assay, a positive result is reported when any 5 or more of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, or 93 kDa. All other banding patterns are reported as negative.

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Borrelia burgdorferi Ab, IgM, IB (CSF)	Negative	(Ref Interval: Negative)

Band(s) present: 23 kDa
(Insufficient number of bands for positive result)

INTERPRETIVE INFORMATION: Borrelia burgdorferi Ab, IgM, IB (CSF)

For this assay, a positive result is reported when any 2 or more of the following bands are present: 23, 39, 41 kDa. All other banding patterns are reported as negative.

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

Lyme Standard 2-Tier Testing, CSF Interp	Negative	(Ref Interval: Negative)

Negative for antibodies to Borrelia species causing Lyme disease. Antibodies detected by the first-tier screen test were not confirmed. Negative results may occur in recently infected patients (less than 14 days).
Repeat testing on a new sample collected in 7-14 days may be helpful.

INTERPRETIVE INFORMATION: Lyme Standard 2-Tier, CSF, 2nd Tier
IgG: For this assay, a positive result is reported when any five or more of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, or 93 kDa. All other banding patterns are reported as negative.

IgM: For this assay, a positive result is reported when any two or more of the following bands are present: 23, 39, or 41 kDa. All other banding patterns are reported as negative.

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier. Lyme disease diagnosis in serum is recommended prior to any CSF studies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Borrelia burgdorferi VlsE1/pepC10 Antibodies, CSF, Total by ELISA With Reflex to IgM and IgG by Immunoblot (Standard Two-Tier Testing, CSF)

ARUP test code 3016760

B. burgdorferi VlsE1/pepC10 Abs, CSF	1.93 IV H	(Ref Interval: <=0.90)

REFERENCE INTERVAL: B. burgdorferi VlsE1/pepC10 Abs, CSF

0.90 IV or less	Negative - VlsE1 and pepC10 antibodies to B. burgdorferi not detected.
0.91-1.09 IV	Equivocal - Repeat testing in 10-14 days may be helpful.
1.10 IV or greater	Positive - VlsE1 and pepC10 antibodies to B. burgdorferi detected.

The detection of antibodies to Borrelia burgdorferi in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier. Lyme disease diagnosis in serum is recommended prior to any CSF studies.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Borrelia burgdorferi Ab, IgG, IB (CSF)	24-040-127335	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Borrelia burgdorferi Ab, IgM, IB (CSF)	24-040-127335	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
B. burgdorferi VlsE1/pepC10 Abs, CSF	24-040-127335	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Lyme Standard 2-Tier Testing, CSF Interp	24-040-127335	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical